LLY8-Kfiled 2026-10-29

Eli Lilly and's results release, filed 2026-10-29

Current report: Results of operations.

Read the filing on sec.gov ↗All documents and exhibits ↗Accession 0000059478-26-000104

What changed

The release's figures as the company tagged them in its 10-Q, filed 2026-10-29.

Latest quarter vs the same quarter a year earlier

10-Q filed 2026-10-29 ↗

Quarter ended	2025-09-30	2026-09-30	Change
Revenue(24,397 − 17,601) ÷ \|17,601\| × 100 = +38.6% ($ millions)	$17.6B	$24.4B	+38.6%
Net income(6,451 − 5,583) ÷ \|5,583\| × 100 = +15.5% ($ millions)	$5.6B	$6.5B	+15.5%
Diluted earnings per share(7.22 − 6.21) ÷ \|6.21\| × 100 = +16.3% ($ a share)	$6.21	$7.22	+16.3%
Diluted share count (weighted)(893 − 899) ÷ \|899\| × 100 = −0.6% (millions of shares)	898.8M	893.4M	−0.6%

Both columns as reported in the latest filing, so a restated prior period shows its restated figure. n/m: not meaningful (the prior figure is zero or of the other sign). Concepts: us-gaap:Revenues, us-gaap:NetIncomeLoss, us-gaap:EarningsPerShareDiluted, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

LLY’s other recent filings

Filed	Form	What it is
2026-10-29	10-Q	Quarterly report, period ended 2026-09-30
2026-08-05	10-Q	Quarterly report, period ended 2026-06-30
2026-08-05	8-K	Current report: Results of operations
2026-05-20	8-K	Current report: Other events sec.gov ↗
2026-05-07	8-K	Current report: Shareholder vote results sec.gov ↗
2026-04-30	10-Q	Quarterly report, period ended 2026-03-31
2026-04-30	8-K	Current report: Results of operations
2026-02-12	10-K	Annual report, fiscal year ended 2025-12-31

Not financial advice. For education only.